Document is current
Any future updates will be listed below
-
Authors
Biersack, Hans J.
Rojas-Fernandez, Alejandro
Ting, Hong-Hoi
Kramer, Vasko
Juweid, Malik E.
Mottaghy, Felix M. https://orcid.org/0000-0002-7212-6521
-
Funding
Funding for this research was provided by:
Universitätsklinikum RWTH Aachen
- License Information
-
More Information
Article History
First Online: 21 February 2025
Declarations
:
: Hans-Jürgen Biersack is medical advisor for NanoMab Technology Ltd. Alejandro Rojas-Fernandez is employer of Berking Theranostics Hamburg, Germany. Hong-Hoi Ting is employer of NanoMab Technology Ltd, chief strategic officer of Full-Life technologies and scientific advisory board member of Radiopharm theranostics. Vasko Kramer is employer of Acrux Radiopharma Consulting SpA. Malik Juweid has nothing to declare.Felix M. Mottaghy is medical advisor for NanoMab Technology Ltd. and Advanced Accelerator Applications (AAA) GmbH/Novartis and has recently received institutional grants from NanoMab Technology Ltd., Siemens, and GE Precision HealthCare LLC. He is also supported by the German Research Foundation (DFG) within the framework of the Research Training Group 2375 “Tumor-targeted Drug Delivery” (grant 331065168), the Clinical Research Unit CRU 5011 “Integrating emerging methods to advance translational kidney research (InteraKD)” (project 445703531). In addition, his research is funded by the German Federal Ministry of Research and Education (project 16GW0319K). Moreover, he is an associate editor of the European Journal of Nuclear Medicine and Molecular Imaging.
